Unknown

Dataset Information

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.


ABSTRACT:

Background

Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17 cell differentiation and exaggerated responsiveness to type I and II interferons. Allogeneic bone marrow transplantation has been attempted in severely affected patients, but outcomes have been poor.

Objective

We sought to define the effect of increased STAT1 activity on T helper cell polarization and to investigate the therapeutic potential of ruxolitinib in treating autoimmunity secondary to STAT1 GOF mutations.

Methods

We used in vitro polarization assays, as well as phenotypic and functional analysis of STAT1-mutated patient cells.

Results

We report a child with a nove

SUBMITTER: Weinacht KG 

PROVIDER: S-EPMC5482293 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature